Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) Growth (1y) (2015 - 2026)
Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 157.80 Bn | 151.14 Bn | 6.27 Bn | -19.74% |
| 2 | Stryker | 115.54 Bn | 112.66 Bn | 3.81 Bn | 14.20% |
| 3 | Medtronic | 103.44 Bn | 95.27 Bn | 5.76 Bn | -11.88% |
| 4 | Boston Scientific | 72.38 Bn | 71.17 Bn | 3.61 Bn | 100.00% |
| 5 | Edwards Lifesciences | 49.76 Bn | 46.09 Bn | 1.29 Bn | 8.20% |
| 6 | Dexcom | 29.53 Bn | 28.42 Bn | 750.30 Mn | 88.89% |
| 7 | GE HealthCare Technologies | 29.51 Bn | 27.44 Bn | 1.98 Bn | -30.89% |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 9 | Steris | 20.69 Bn | 20.27 Bn | 697.10 Mn | 47.37% |
| 10 | Pacific Biosciences Of California | 418.97 Mn | 143.01 Mn | 12.84 Mn | 97.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.92% |
| Dec 31, 2025 | 70.45% |
| Sep 30, 2025 | 40.91% |
| Jun 30, 2025 | 78.13% |
| Mar 31, 2025 | -396.55% |
| Dec 31, 2024 | -41.94% |
| Sep 30, 2024 | 15.38% |
| Jun 30, 2024 | -128.57% |
| Mar 31, 2024 | 19.44% |
| Dec 31, 2023 | 16.22% |
| Sep 30, 2023 | 23.53% |
| Jun 30, 2023 | 12.50% |
| Mar 31, 2023 | 2.70% |
| Dec 31, 2022 | -12.12% |
| Jun 30, 2022 | -52.38% |
| Mar 31, 2022 | 17.78% |
| Dec 31, 2021 | -171.74% |
| Jun 30, 2021 | -40.00% |
| Mar 31, 2021 | -4,600.00% |
| Mar 31, 2020 | 105.00% |